Update - InspireMD Announces CGuard(TM) Approval in

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Update - InspireMD Announces CGuard(TM) Approval in Colombia

BOSTON, MA--(Marketwired - Oct 5, 2015) - InspireMD, Inc. ( NYSE MKT : NSPR ) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced today that it has received regulatory approval to commercialize the CGuard™ Embolic Prevention System for the treatment of carotid artery disease in Colombia. The approval was granted by the Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA). The global carotid stent market is expected to grow at a compound average annual rate of 13% in 2014-2019, according to Research and Markets. By region, the Latin American market is expected to expand at a strong rate, driven by endovascular procedure volume growth and the adoption of premium priced products, according to Millennium Research Group.

Alan Milinazzo, CEO of InspireMD commented, "CGuard™ approval in Colombia is an important milestone for the Company and another critical validation for our technology. We are methodically, and successfully, bringing this important technology to key markets around the world."

As previously noted, six month results from the Company's CGuard™ clinical trial, CARENET (CARotid Embolic protection using MicroNET) showed a 100% procedural success rate with a 3.6% MACCE (major adverse cardiac and cerebrovascular event) rate vs. comparative data of 8.09%. Six month ultrasound analysis also indicated healthy healing without restenosis concern with patent external and internal carotid arteries. In addition, the investigator-led all comer PARADIGM study continues to document both the short term and long term benefits of using the MicroNet™ covered CGuard™ technology in patients with carotid artery disease.

Mr. Milinazzo concluded, "We are well focused on driving our business forward, with other recent announcements that include the full commercial launch of CGuard™ in Europe with our strategic distribution partner, Penumbra, Inc. ( NYSE : PEN ), expanding intellectual property coverage, continuing broad collaboration discussions that leverage our MicroNet™ technology while advancing our development program for our neurovascular platform, and our highly disciplined cash management program."

About InspireMD, Inc.

InspireMD ( www.inspiremd.com ) seeks to utilize its proprietary MGuard™ with MicroNet™ technology to make its products the industry standard for embolic protection and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events.

InspireMD intends to pursue applications of this MicroNet technology in coronary, carotid (CGuard™), neurovascular, and peripheral artery procedures. InspireMD's common stock is quoted on the NYSE MKT under the ticker symbol NSPR.

About CGuard™ EPS

The proprietary CGuard™ Embolic Prevention System (EPS) uses the same MicroNet™ technology featured on the MGuard™ and MGuard Prime™ coronary Embolic Protection Systems. The CGuard™ EPS is designed to prevent peri-procedural and late embolization by trapping potential emboli against the arterial wall while maintaining excellent perfusion to the external carotid artery and branch vessels.

MicroNet™ is a bio-stable mesh woven from a single strand of 20 micron Polyethylene Terephthalate.

CGuard™ EPS is CE Marked and not approved for sale in the U.S. by the U.S. Food and Drug Administration at this time.

About PARADIGM

PARADIGM is an investigator-initiated " P" rospective evaluation of " A" ll-comer pe" R" cutaneous c" A" roti" D" revascularization " I" n symptomatic and increased-risk asymptomatic carotid artery stenosis, using C" G" uard™ " M" esh-covered embolic prevention stent system. At EuroPCR 2015, Dr. Musialek summarized his clinical presentation of 71 CGuard procedures in unselected all-comer patients in the PARADIGM evaluation as: 1) stent system success and procedure success rate of 100%; 2) periprocedural complications of 0%, and remained at 0% at 30 days; and 3) no MACNE occurred periprocedurally or at 30 days, by operator-independent neurologist and non-invasive cardiologist evaluation.

Forward-looking Statements

This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov . The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Investor Contacts: InspireMD, Inc. Craig Shore Chief Financial Officer Phone: 1-888-776-6804 Email: craigs@inspiremd.com PCG Advisory Vivian Cervantes Investor Relations Phone: (212) 554-5482

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 270

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
AutoShop Answers Extends 2027 Training Into Fridays

Updated Category News Views 0

A repair bay can hum all day while the back office quietly bleeds profit. That unglamorous reality is why AutoShop Answers adding nine Friday specialty classes to its 2027 Key2Key Weekend calendar deserves a closer look. This is not a new tool chest or some vague motivational roadshow; it is an attempt to give independent shop owners an extra day to work on the pieces...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 410

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 45

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 385

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
EyePoint Lawsuit Puts DURAVYU Claims Under a Microscope

Updated Category News Views 0

Nothing makes biotech investors reach for the aspirin faster than a lawsuit centered on whether a drug worked as advertised. EyePoint, Inc. is facing a proposed federal securities class action alleging that the company overstated the effectiveness of DURAVYU and, by extension, its clinical, regulatory, and commercial prospects. That is a serious allegation, but it remains...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 191

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding Investor Sentiment and Trends on SNAP Options

Updated Category News Views 251

Understanding Investor Sentiment and Trends on SNAP Options Investors are showing an intriguing trend towards Snap (NASDAQ: SNAP) as they engage in notable options trading activities, indicating a potential shift in market dynamics that shouldn't be overlooked. Our examination of public options records reveals that significant players are backing a more optimistic outlook...

Continue Reading
StarKist Partners with Kyle Busch Family for Exciting Season

Updated Category News Views 202

StarKist and the Busch Family Kick Off NASCAR 2026 As the exhilarating NASCAR season launches, StarKist Co. is excited to announce its partnership with NASCAR champion Kyle Busch, wellness advocate Samantha Busch, and young racer Brexton Busch. Building upon a successful initial year, this collaboration emphasizes the importance of healthy, ready-to-eat protein options...

Continue Reading
Teva's Upcoming Presentations at Leading Healthcare Conferences

Updated Category News Views 166

Teva's Upcoming Presentations at Major Investor Conferences In a significant announcement, Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is set to showcase its commitment to healthcare innovation. Richard Francis, the esteemed President and CEO of Teva, will represent the company at two prestigious investor conferences this September. Morgan Stanley Global Healthcare...

Continue Reading
Earth Animal Celebrates the Holiday Season with Giving Back

Updated Category News Views 63

Earth Animal's Heartwarming Holiday Initiative This holiday season, Earth Animal has kicked off a touching initiative called "Buy Joy to Gift Joy," which aims to make a difference in the lives of shelter dogs. In collaboration with Greater Good Charities, for every Pumpkin Spice or Holiday Feast No-Hide Chew sold, the company will donate one No-Hide® Strip to a shelter...

Continue Reading
Elderly American Sentenced in Russia Amid Rising Tensions

Updated Category News Views 71

Understanding the Sentencing of Stephen Hubbard A Moscow court has sentenced Stephen Hubbard, a 72-year-old American citizen, to six years and 10 months in prison for alleged involvement in combat against Russian forces alongside a Ukrainian unit. This case marks a significant moment, as it is the first instance of an American receiving imprisonment on 'mercenary' grounds...

Continue Reading